These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 4211429)

  • 21. Study of dose-dependent metabolism of 5,5-diphenyl-hydantoin in the rat using new methodology for isolation and quantitation of metabolites in vivo and in vitro.
    Gerber N; Weller WL; Lynn R; Rangno RE; Sweetman BJ; Bush MT
    J Pharmacol Exp Ther; 1971 Sep; 178(3):567-79. PubMed ID: 5571905
    [No Abstract]   [Full Text] [Related]  

  • 22. Phenytoin and ayurvedic preparation--clinically important interaction in epileptic patients.
    Kshirsagar NA; Dalvi SS; Joshi MV; Sharma SS; Sant HM; Shah PU; Chandra RS
    J Assoc Physicians India; 1992 May; 40(5):354-5. PubMed ID: 1484013
    [No Abstract]   [Full Text] [Related]  

  • 23. Interaction between metronidazole and drugs eliminated by oxidative metabolism.
    Jensen JC; Gugler R
    Clin Pharmacol Ther; 1985 Apr; 37(4):407-10. PubMed ID: 3979002
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum concentrations of diphenylhydantoin (phenytoin) and phenobarbital and their relation to therapeutic and toxic effects.
    Buchthal F; Svensmark O
    Psychiatr Neurol Neurochir; 1971; 74(2):117-36. PubMed ID: 5004709
    [No Abstract]   [Full Text] [Related]  

  • 25. Effects of physical stress on the disposition of drugs eliminated by the liver in man.
    Swartz RD; Sidell FR; Cucinell SA
    J Pharmacol Exp Ther; 1974 Jan; 188(1):1-7. PubMed ID: 4809269
    [No Abstract]   [Full Text] [Related]  

  • 26. Antipyrine disposition in relation to lowered anticonvulsant plasma level during pregnancy.
    Chiba K; Ishizaki T; Tabuchi T; Wagatsuma T; Nakazawa Y
    Obstet Gynecol; 1982 Nov; 60(5):620-6. PubMed ID: 6815599
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Seizures following reduction in phenytoin level after orally administered folic acid.
    Steinweg DL; Bentley ML
    Neurology; 2005 Jun; 64(11):1982. PubMed ID: 15955964
    [No Abstract]   [Full Text] [Related]  

  • 28. Decreases in phenytoin hydroxylation activities catalyzed by liver microsomal cytochrome P450 enzymes in phenytoin-treated rats.
    Yamazaki H; Komatsu T; Takemoto K; Saeki M; Minami Y; Kawaguchi Y; Shimada N; Nakajima M; Yokoi T
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 1):427-34. PubMed ID: 11259327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Therapy of the status epilepticus].
    Nervenarzt; 1994 Jan; 65(1 Suppl [therapie]):1-8. PubMed ID: 9218057
    [No Abstract]   [Full Text] [Related]  

  • 30. Correlations between cytochrome P-450 and oxidative metabolism of benzo[a]pyrene and 7-ethoxycoumarin in human liver in vitro and antipyrine elimination in vivo.
    Pelkonen O; Sotaniemi E; Tokola O; Ahokas JT
    Drug Metab Dispos; 1980; 8(4):218-22. PubMed ID: 6105054
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebellar atrophy in an epileptic child: is it due to phenytoin?
    Ahuja SR; Karande S; Kulkarni MV
    J Postgrad Med; 2000; 46(4):278-9. PubMed ID: 11435657
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic and environmental factors affecting drug response in man.
    Vesell ES
    Fed Proc; 1972; 31(4):1253-69. PubMed ID: 4114107
    [No Abstract]   [Full Text] [Related]  

  • 33. CYP2C-catalyzed delta9-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin.
    Bland TM; Haining RL; Tracy TS; Callery PS
    Biochem Pharmacol; 2005 Oct; 70(7):1096-103. PubMed ID: 16112652
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Irreversible binding of 3-14C-antipyrine to hepatic protein in vivo and in metabolizing liver microsomes.
    Tabarelli-Poplawski S; Uehleke H
    Naunyn Schmiedebergs Arch Pharmacol; 1977 Mar; 297(1):105-10. PubMed ID: 859644
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the in vivo and in vitro rates of formation of the three main oxidative metabolites of antipyrine in man.
    Boobis AR; Brodie MJ; Kahn GC; Toverud EL; Blair IA; Murray S; Davies DS
    Br J Clin Pharmacol; 1981 Dec; 12(6):771-7. PubMed ID: 7340879
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acute intoxication with 5,5-diphenylhydantoin (Dilantin) associated with impairment of biotransformation. Plasma levels and urinary metabolites; and studies in healthy volunteers.
    Gerber N; Lynn R; Oates J
    Ann Intern Med; 1972 Nov; 77(5):765-71. PubMed ID: 4628215
    [No Abstract]   [Full Text] [Related]  

  • 37. Mechanism of hepatic drug oxidation and its relationship to individual differences in rates of oxidation in man.
    Davies DS; Thorgeirsson SS
    Ann N Y Acad Sci; 1971 Jul; 179():411-20. PubMed ID: 5285386
    [No Abstract]   [Full Text] [Related]  

  • 38. Antipyrine pharmacokinetics in the pregnant rat.
    Dean M; O'Donnell L; Penglis S; Stock B
    Drug Metab Dispos; 1980; 8(4):265-7. PubMed ID: 6105062
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Induction of liver microsomal enzymes in epileptics under treatment with carbamazepine].
    Mapelli G; Pavoni M; Currò Dossi B; Huber R
    Riv Neurol; 1983; 53(2):127-37. PubMed ID: 6136087
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The treatment of epilepsy with falepsin. A report of the clinical experience gained].
    Krüger E; Rabending G
    Psychiatr Neurol Med Psychol (Leipz); 1968 Oct; 20(10):393-6. PubMed ID: 4974361
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.